The Act on the Reform of the Market for Medicinal Products (AMNOG) has completely revised pricing regulations for newly authorized pharmaceuticals and their reimbursement by statutory health insurance (SHI) providers. Since 2011, findings from benefit evaluations of new medicines by the Federal Joint Committee (G-BA) form the basis for price negotiations between manufacturers and the SHI. The reimbursement price is defined as a rebate on the drug price at launch.
AMNOG Pricing Analysis
advisors in healthcare has developed a tool that overviews the outcomes of AMNOG price negotiations. The underlying dataset contains detailed information on all benefit assessments as well as final negotiated rebates to date. The basis for the evaluation of rebates are price information published by the official German drug price list “Lauertaxe”. If one new pharmaceutical was subject to more than one assessment, we considered the latest rebate update.